Vancouver, B.C. – TheNewswire – September 18, 2020 – Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS) announces that further to its news release dated August 27, 2020, it has received the TSX Venture Exchange Final Approval for the Shares for Debt Transaction whereby 1,007,600 Common Shares of the Company were issued in order to settle a debt of $100,760.
All Common Shares issued in connection with the Transaction are subject to resale restrictions for a period of four months and one day under applicable securities legislation.
About Solarvest:
Solarvest BioEnergy Inc. is an algae biotechnology company whose production platform provides it with an extremely flexible system capable of producing numerous valuable products from Organic Omega-3 fatty acids to therapeutic proteins/active ingredients. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein, recombinant viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.
For further information contact:
Gerri Greenham, Chief Executive Officer
Email: [email protected]
The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the Company’s expectations and projections.
Copyright (c) 2020 TheNewswire – All rights reserved.